These studies clarify that PTP1B is a target for the treatment of type 2 diabetes and obesity and indicate that PTP1B inhibitors could effectively treat type 2 diabetes and obesity by improving insulin sensitivity (7). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.